As shown in Table 2, after seven days of treatment (T1), COVID-19 patients belonging to group A (not receiving canrenone) showed a significant improvement in [K+]plasma (4.6 mmol/L, p < 0.001), CRP (2.2 mg/dL), IL-6 (13 pg/mL), and ΔA-aO2 (135 mmHg). The gene discussed is IL6; the disease is COVID-19.